LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Ligand Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

164.98 -0.52

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

162

Макс.

167.49

Ключевые показатели

By Trading Economics

Доход

47M

4.8M

Продажи

2.3M

48M

P/E

Средняя по отрасли

47.016

35.664

Рентабельность продаж

10.177

Сотрудники

68

EBITDA

50M

9.7M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+9.85% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

637M

3.2B

Предыдущая цена открытия

165.5

Предыдущая цена закрытия

164.98

Новостные настроения

By Acuity

48%

52%

153 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Ligand Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 сент. 2025 г., 23:37 UTC

Популярные акции

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 сент. 2025 г., 20:41 UTC

Отчет

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 сент. 2025 г., 20:30 UTC

Отчет

GameStop 2Q Sales, Profit Rise

9 сент. 2025 г., 23:19 UTC

Обсуждения рынка

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 сент. 2025 г., 21:35 UTC

Отчет

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 21:32 UTC

Отчет

Oracle's Backlog Swells With Big Customer Deals -- Update

9 сент. 2025 г., 21:02 UTC

Приобретения, слияния, поглощения

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 сент. 2025 г., 20:33 UTC

Отчет

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 сент. 2025 г., 20:26 UTC

Отчет

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 20:23 UTC

Отчет

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 сент. 2025 г., 20:12 UTC

Отчет

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 сент. 2025 г., 20:10 UTC

Отчет

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 сент. 2025 г., 20:10 UTC

Отчет

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 сент. 2025 г., 20:09 UTC

Отчет

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 сент. 2025 г., 20:09 UTC

Отчет

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 сент. 2025 г., 20:08 UTC

Отчет

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 сент. 2025 г., 20:07 UTC

Отчет

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 сент. 2025 г., 20:06 UTC

Отчет

Oracle 1Q Software Revenue $5.72B >ORCL

9 сент. 2025 г., 20:06 UTC

Отчет

Synopsys 3Q Adj EPS $3.39 >SNPS

9 сент. 2025 г., 20:06 UTC

Отчет

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Rev $14.93B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q EPS $1.01 >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Synopsys 3Q EPS $1.50 >SNPS

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Services Revenue $1.35B >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Adj EPS $1.47 >ORCL

9 сент. 2025 г., 20:05 UTC

Отчет

Oracle 1Q Hardware Revenue $670M >ORCL

Сравнение c конкурентами

Изменение цены

Ligand Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

9.85% рост

Прогноз на 12 месяцев

Средняя 182.2 USD  9.85%

Максимум 206 USD

Минимум 155 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Ligand Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

102.5 / 109.24Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Very Strong Bearish Evidence

Долгосрочная

Weak Bullish Evidence

Настроения

By Acuity

153 / 371Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat